| 25/04/24 | 15:46:56 | 25 Apr 2024 | | Change of Name |
| 22/04/24 | 10:11:56 | 22 Apr 2024 | | Holding(s) in Company |
| 11/04/24 | 15:04:50 | 11 Apr 2024 | | Holding(s) in Company |
| 09/04/24 | 07:00:12 | 9 Apr 2024 | | Holding(s) in Company |
| 08/04/24 | 16:03:15 | 8 Apr 2024 | | Holding(s) in Company |
| 05/04/24 | 15:39:31 | 5 Apr 2024 | | Director/PDMR Shareholding |
| 05/04/24 | 14:40:59 | 5 Apr 2024 | | Holding(s) in Company |
| 04/04/24 | 13:59:09 | 4 Apr 2024 | | Result of General Meeting |
| 04/04/24 | 07:00:05 | 4 Apr 2024 | | Result of Retail Offer |
| 19/03/24 | 17:03:43 | 19 Mar 2024 | | Retail Offer |
| 19/03/24 | 17:00:00 | 19 Mar 2024 | | Acquisition, Fundraising and Change of Name |
| 27/02/24 | 07:00:10 | 27 Feb 2024 | | SFX-01 positive update in bowel cancer models |
| 19/02/24 | 11:22:01 | 19 Feb 2024 | | Positive update on SFX-01 in vitro GBM studies |
| 09/02/24 | 11:01:01 | 9 Feb 2024 | | Notice of Dispute lodged with Stalicla SA |
| 16/01/24 | 15:07:32 | 16 Jan 2024 | | Series B Fund Raise by partner, Stalicla SA |
| 29/12/23 | 11:29:54 | 29 Dec 2023 | | Holding(s) in Company |
| 22/12/23 | 07:00:06 | 22 Dec 2023 | | Directorate Changes |
| 13/11/23 | 07:00:14 | 13 Nov 2023 | | Upcoming conferences |
| 31/10/23 | 07:00:12 | 31 Oct 2023 | | Half-year Report |
| 26/10/23 | 07:00:14 | 26 Oct 2023 | | Erasmus Medical Center begins glioblastoma studies |
| 19/10/23 | 14:26:29 | 19 Oct 2023 | | Authored Article Publication |
| 05/09/23 | 07:00:06 | 5 Sept 2023 | | Directorate Changes |
| 15/08/23 | 07:00:03 | 15 Aug 2023 | | Final Report from Phase 1b PK/PD study |
| 03/08/23 | 12:38:35 | 3 Aug 2023 | | Rule 17 Disclosure |
| 02/08/23 | 07:00:03 | 2 Aug 2023 | | Return of rights to Sulforadex from Juvenescence |
| 21/07/23 | 12:02:59 | 21 Jul 2023 | | Result of AGM |
| 27/06/23 | 07:00:05 | 27 Jun 2023 | | SFX-01 radiosensitisation effect confirmed in-vivo |
| 20/06/23 | 13:59:34 | 20 Jun 2023 | | Notice of AGM & Posting of Annual Report |
| 19/06/23 | 07:00:04 | 19 Jun 2023 | | Grant Success for Glioblastoma studies |
| 07/06/23 | 07:00:03 | 7 Jun 2023 | | Final Results |
| 26/05/23 | 11:00:01 | 26 May 2023 | | Notice of Results |
| 22/03/23 | 07:00:05 | 22 Mar 2023 | | Preliminary results from Phase 1b study |
| 16/03/23 | 14:00:19 | 16 Mar 2023 | | Price Monitoring Extension |
| 16/03/23 | 11:05:36 | 16 Mar 2023 | | Second Price Monitoring Extn |
| 16/03/23 | 11:00:25 | 16 Mar 2023 | | Price Monitoring Extension |
| 16/03/23 | 07:00:07 | 16 Mar 2023 | | Further evidence of radiosensitisation by SFX-01 |
| 13/03/23 | 07:00:07 | 13 Mar 2023 | | No exposure to Silicon Valley Bank |
| 25/01/23 | 07:00:04 | 25 Jan 2023 | | Clinical trial update |
| 14/12/22 | 17:08:04 | 14 Dec 2022 | | Grant of Options - Director/PDMR Shareholding |
| 08/12/22 | 07:00:03 | 8 Dec 2022 | | Half-year Report |
| 02/12/22 | 07:00:12 | 2 Dec 2022 | | Notice of Half Year Results |
| 30/11/22 | 14:06:03 | 30 Nov 2022 | | Second Price Monitoring Extn |
| 30/11/22 | 14:00:34 | 30 Nov 2022 | | Price Monitoring Extension |
| 16/11/22 | 07:00:04 | 16 Nov 2022 | | Study started of new SFX-01 tablet formulation |
| 21/10/22 | 11:05:32 | 21 Oct 2022 | | Second Price Monitoring Extn |
| 21/10/22 | 11:00:34 | 21 Oct 2022 | | Price Monitoring Extension |
| 12/10/22 | 16:41:03 | 12 Oct 2022 | | Second Price Monitoring Extn |
| 12/10/22 | 16:35:33 | 12 Oct 2022 | | Price Monitoring Extension |
| 12/10/22 | 07:00:03 | 12 Oct 2022 | | Clinical trial update |
| 10/10/22 | 11:05:49 | 10 Oct 2022 | | Second Price Monitoring Extn |
